A CBD Product Line Could Deliver A 25% Gain
Aphria Inc. (NYSE: APHA) is a Health Canada Licensed Producer of medical cannabis products. Its medical cannabis is 100% greenhouse grown.
The company recently announced news that has investors talking:
Aphria Inc., through its subsidiary Aphria Deutschland GmbH, launched its first CBD-based nutraceutical, the first product in its CBD-based cosmetics line for the German market.
Featuring CBD derived from hemp, the CannRelief brand of products are being produced in the European Union and distributed by the Company’s subsidiary, CC Pharma, which has access to more than 13,000 pharmacies throughout Germany.
Motley Fool’s Top 2019 Stock For The Marijuana BoomSponsored Content
We recommended this stock before the marijuana boom and while it’s grown 490% since, we have a very strong conviction this is just the beginning…
Jakob Ripshtein, President of Aphria, commented:
“We are excited to introduce our first brand of CBD products for the German nutraceutical and cosmetics market.
Supported by our extensive distribution network through CC Pharma, CannRelief provides a natural extension to Aphria’s growing business opportunities in the German medical cannabis market.
We look forward to providing a full range of CannRelief CBD products this year.”
CannRelief CBD oils are being sold in stores across Germany, in both a 5% and 10% CBD concentration.
In a phased rollout in 2019, a range of skincare and other products, including creams, serums and masks will be introduced under the CannRelief brand.
Ripshtein continued: “Aphria continues to execute on its strategic growth initiatives in Germany. We believe we have tremendous momentum in Germany and across our international business as we continue to strengthen our global footprint.”
As Benzinga reported,
“The European CBD market is fairly small but is poised for a tremendous growth in the near future driven by demand among consumers, high spending in the region, and an ease in regulations that might be catalyzed by the UN’s decision regarding CBD that has recently been requested by the World Health Organization.
In a recent report, Brightfield Group said European CBD market could reach $1.7 billion by 2023, registering a CAGR of 42 percent. Germany is expected to be the leading market with a share of $605 million.”
The company has been recognized for its top-tier production, and as a result, could easily secure long-term supply deals, as well as attract brand-name partners.
In addition to growth initiatives in Germany, the company retains a unique approach to cannabis production, and with revenues set to hit $1 billion by 2020, there is substantial upside for the stock.
APHA should be considered a buy if momentum increases.
Look for an entry at $10.00 with a price target of at least $12.50 based on the pattern in the chart.